Lung Diseases, InterstitialNCT04707781
Database for Interstitial Lung Disease
An observational study of Lung Diseases, Interstitial, run by Medical University of Graz at 1 site in Austria.
Trial summary
The purpose of this study is to establish a clinical database for patients bearing at risk for ILD (Interstitial Lung Disease) and to set up a prospective ILD Screening program for these patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Diseases, Interstitial
- What is being tested?
- chest CT
- How many people
- 412 participants
- Where
- 1 siteAustria
- Study dates
- 1 May 2021to 31 Jan 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients (females and males; above 18 yrs) with a known systemic disease bearing a risk for ILD but without diagnosed ILD and patients (females and males; above 18 yrs) with diagnosed ILD.
Who may be able to join
- Age: ≥ 18 years
- patients with a known systemic disease bearing a risk for ILD
- signed informed consent (for prospective part)
Who cannot join
- Age < 18 years
- comorbidities severely limiting life-expectancy (e.g. severe cardiovascular conditions, malignant disease)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Austria1 site, 1 recruiting
- Recruiting
Medical University of Graz, Department of Internal Medicine, Division of Pulmonology
Graz, 8036
Gabor Kovacs, MD, +43-316-385-80748, gabor.kovacs@klinikum-graz.at
Katarina Zeder, MD, katarina.zeder@medunigraz.at
About this study
Official title: Clinical Database for the Early Recognition of Pulmonary Parenchymal Involvement in Patients With Systemic Diseases Bearing a Risk for Interstitial Lung Disease
The purpose of this study is to establish a clinical database for patients bearing at risk for ILD (Interstitial Lung Disease) and to set up a prospective ILD Screening program for these patients.
- Conditions
- Lung Diseases, Interstitial
- Being tested
- chest CT
- Medical subject headings
- Lung Diseases, Interstitial
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
chest CTDiagnostic test
assessment of interstitial lung disease using chest CT
| Study group | Role | What they receive |
|---|---|---|
| prospective patient cohort | patients who will undergo the prospective ILD Screening algorithm Receives: Diagnostic Test: chest CT | |
| retrospective patient cohort | patients with diagnosed ILD Receives: Diagnostic Test: chest CT |
What is being measured
The primary outcome is the main question the study is designed to answer.
DLCO%pred (carbon monoxide diffusing capacity) at time of ILD diagnosis
The investigators aim to assess DLCO% pred at time of ILD diagnosis in patients undergoing a ILD Screening algorithm and compare to the retrospective patient cohort with diagnosed ILD and the DLCO%pred at time of ILD diagnosis
Measured: 5 years
Secondary outcomes (1)
FVC%pred (Forced vital capacity) at time of ILD diagnosis
The investigators aim to assess FVC% pred at time of ILD diagnosis in patients undergoing a ILD Screening algorithm and compare to the retrospective patient cohort with diagnosed ILD and the FVC%pred at time of ILD diagnosis
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2021
- Study start1 May 2021
- Primary completion31 Jan 2029 (estimated)
- Study completion31 Jan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Diseases, InterstitialStudies of the same condition, open and under way.
- More trials run by Medical University of GrazThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 412 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medical University of Graz
- Sponsor type
- University, hospital or other
- Collaborators
- Boehringer Ingelheim
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04707781
- Sponsor's protocol ID
- 33-023 ex 20/21
- Status last verified
- Jan 2026
- First submitted
- 12 Jan 2021
- Last updated
- 15 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 15 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Database for the Early Recognition of Pulmonary Parenchymal Involvement in Patients With Systemic Diseases Bearing a Risk for Interstitial Lung Disease
- ClinicalTrials.gov ID
- NCT04707781
- Acronym / sponsor ID
- 33-023 ex 20/21
- Conditions
- Lung Diseases, Interstitial
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 412 participants (estimated)
- Lead sponsor
- Medical University of GrazUniversity, hospital or other
- Collaborators
- Boehringer Ingelheim
- Study start
- 1 May 2021 (actual)
- Primary completion
- 31 Jan 2029 (estimated)
- Study completion
- 31 Jan 2029 (estimated)
- First posted
- 13 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to establish a clinical database for patients bearing at risk for ILD (Interstitial Lung Disease) and to set up a prospective ILD Screening program for these patients.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| prospective patient cohort | – | Diagnostic Test: chest CTpatients who will undergo the prospective ILD Screening algorithm |
| retrospective patient cohort | – | Diagnostic Test: chest CTpatients with diagnosed ILD |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients (females and males; above 18 yrs) with a known systemic disease bearing a risk for ILD but without diagnosed ILD and patients (females and males; above 18 yrs) with diagnosed ILD.
Key inclusion criteria (3 listed)
- Age: ≥ 18 years
- patients with a known systemic disease bearing a risk for ILD
- signed informed consent (for prospective part)
Key exclusion criteria (2 listed)
- Age < 18 years
- comorbidities severely limiting life-expectancy (e.g. severe cardiovascular conditions, malignant disease)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| chest CTassessment of interstitial lung disease using chest CT | Diagnostic test | prospective patient cohort, retrospective patient cohort |
Primary outcome
DLCO%pred (carbon monoxide diffusing capacity) at time of ILD diagnosis
Time frame: 5 years
The investigators aim to assess DLCO% pred at time of ILD diagnosis in patients undergoing a ILD Screening algorithm and compare to the retrospective patient cohort with diagnosed ILD and the DLCO%pred at time of ILD diagnosis
1 secondary outcome
FVC%pred (Forced vital capacity) at time of ILD diagnosis
Time frame: 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Lung Diseases, Interstitial
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
RecruitingPhase 2
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
RecruitingPhase 2
Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease
Fibrotic Interstitial Lung Disease
RecruitingObservational study
Real-world Study of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
RecruitingObservational study
Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome
Hermansky-Pudlak Syndrome (HPS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Diseases, Interstitial, run by Medical University of Graz at 1 site in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gabor Kovacs, MD (+43-316-385 ext. 12183, gabor.kovacs@klinikum-graz.at), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
DLCO%pred (carbon monoxide diffusing capacity) at time of ILD diagnosis (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2026.